Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-Transplant Cyclophosphamide in Pediatric Refractory AML
NCT03654703Phase 2Unknown
- Sponsor
- Capital Institute of Pediatrics
- Start
- Mar 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cyclophosphamide in acute myeloid leukemia (AML) (2 arms), sponsored by Capital Institute of Pediatrics. Primary endpoint: Disease status at 1 year. Status: unknown.
02
Drugs
cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03654703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654703.